PhenylalaninePhe · F

In brief

The molecule

Phenylalanine is alanine with a benzene ring attached: a benzyl side chain of seven carbons, six of them in a flat aromatic ring. It is among the most hydrophobic of the amino acids, so in proteins it sits buried in the core, stacking against other rings.

The ring has no hydroxyl group. Adding one, at the far end, is the single change that turns phenylalanine into tyrosine, and the enzyme that does it, phenylalanine hydroxylase, is one of a family of three related hydroxylases that also make the precursors of dopamine and serotonin ².

Where it comes from

The body cannot make the benzene ring, so phenylalanine is essential. Plants and bacteria build it from sugar by the shikimate pathway, which animals lack ⁸. In plants, that pathway runs further than the textbooks could say until recently. The phenylalanine ammonia-lyase route to salicylic acid — the parent compound of aspirin — was incomplete for decades, and has now been fully characterized in rice: a cinnamoyl-CoA ligase converts trans-cinnamic acid to cinnamoyl-CoA, peroxisomal β-oxidation makes benzoyl-CoA, a peroxisomal benzoyltransferase makes benzyl benzoate, an endoplasmic-reticulum cytochrome P450 hydroxylates it to benzyl salicylate, and a cytosolic carboxylesterase hydrolyzes that to salicylic acid. Evolutionary analysis places the pathway's assembly before the divergence of gymnosperms, and activating it in rice raised salicylic acid and plant immunity ⁹. The trans-cinnamic acid that the PKU drug pegvaliase makes as waste is a plant hormone's starting material.

Requirements are set for phenylalanine and tyrosine together, because tyrosine is made from phenylalanine and spares it: 25 mg per kilogram a day for adults ¹. When phenylalanine intake was fixed at 9 mg/kg, adult men needed about 6 mg/kg of tyrosine on average, and the authors put the total aromatic amino acid need at 21 mg/kg ⁵.

EssentialMust come from food. The adult requirement for phenylalanine and tyrosine together is 25 mg per kilogram a day ¹; with phenylalanine held at 9 mg/kg, adult men needed about 6 to 7 mg/kg of tyrosine on top ⁵.

In the bottle · fermentedIndustrial phenylalanine is made by fermentation in engineered Escherichia coli or Corynebacterium glutamicum, which build it from glucose through the shikimate pathway ⁸. It is the same molecule as in food.

What the body does with it

Most phenylalanine that is not built into protein is converted to tyrosine in the liver. Phenylalanine hydroxylase is a 452-amino-acid enzyme that assembles into a tetramer and switches between a resting and an activated shape; phenylalanine binding to its regulatory domain is what activates it, so the enzyme speeds up when phenylalanine is plentiful ^2,12. It does not do that alone. DNAJC12, a J-domain co-chaperone, binds phenylalanine hydroxylase — preferentially the phenylalanine-activated form, whose shape resembles unliganded tyrosine hydroxylase — with four chaperone monomers per enzyme tetramer at saturation. It protects the tetramer from aggregation and LOWERS the phenylalanine concentration needed to activate the enzyme, without touching its interaction with BH4, and it also stabilizes and delays aggregation of the PKU variant p.R261Q ¹³. DNAJC12 variants cause hyperphenylalaninemia in patients, which makes the chaperone a cause of raised phenylalanine in its own right, outside both the enzyme and its cofactor.

From tyrosine come the catecholamines, dopamine, noradrenaline and adrenaline; the thyroid hormones, built on tyrosines of thyroglobulin; and melanin ^2,3. A phenylalanine that cannot be hydroxylated therefore causes two problems at once: an excess of phenylalanine and a shortage of what lies downstream ¹⁰.

The cofactor of the hydroxylation, tetrahydrobiopterin, is recycled and partly salvaged by the cell, and it serves the tyrosine and tryptophan hydroxylases and nitric oxide synthase as well ¹⁴.

Phenylalanine also has a job that has nothing to do with tyrosine. In human memory CD4 T cells, raised intracellular L-phenylalanine pushes the cell towards glycolysis and away from oxidative phosphorylation — in CD4, memory CD4 and Th2 cells, but not in Th1, Th17 or regulatory T cells. It restrains the proliferation of memory CD4, Th2 and Th17 cells in an IL4I1-dependent way, and limits Th2 differentiation by inhibiting STAT6 and mTOR signaling. In allergy, LAT1-dependent transport of phenylalanine INTO Th2 cells was impaired, with more intracellular processing and expansion of pathogenic Th2 cells ¹⁵. On that reading phenylalanine is a brake on the allergic arm of the immune system, acting through the same transporter this page already lists for the blood–brain barrier.

How it is made, moved and broken down

When phenylalanine hydroxylase is missing, phenylalanine builds up in blood and is diverted into minor pathways, including transamination to phenylpyruvic acid, the compound Asbjørn Følling found in the urine of affected people in 1934 and that gave the disease its first name, imbecillitas phenylpyrouvica ¹⁹.

There is one fate of phenylalanine this page did not have at all, and it is the one with a drug company behind it. N-lactoyl-phenylalanine, Lac-Phe, is lactate joined to phenylalanine by carnosine dipeptidase 2; it rises acutely with exercise and with eating, and in animals it suppresses appetite and reduces body weight ²⁰. The mechanism has now been narrowed: Lac-Phe directly inhibits hypothalamic AgRP neurons, which indirectly activates anorexigenic neurons in the paraventricular nucleus, and both halves are needed. The inhibition works through the ATP-sensitive potassium channel, and blocking that channel blunts the effect ²¹. Metformin raises circulating Lac-Phe and produces similar appetite suppression; beyond metabolism it pushes macrophages towards an anti-inflammatory state and protects in mouse models of colitis and spinal cord injury; the first human trial in obesity began dosing in 2025; and its receptor, its transporters and the tissues that make it are all still undefined ²⁰. Lac-Phe is also raised in mitochondrial disease, in sepsis, and in phenylketonuria itself.

Carbon skeleton · glucogenic and ketogenicThrough tyrosine, its carbons end as fumarate, which can make glucose, and acetoacetate, a ketone body ²².

Where it matters most

Liver

The main site of phenylalanine hydroxylase, and so where phenylalanine becomes tyrosine ¹⁰.

Brain

Where PKU does its damage. With plasma phenylalanine near 1,000 µmol/L, brain levels were about 250 and rose further after a load ¹⁶.

Placenta and fetus

Phenylalanine crosses the placenta on LAT1, so a mother’s high level reaches the fetus and injures a baby who does not itself have PKU ^17,24.

Kidney tubule

Phenylalanine primes the tubule for calcium oxalate crystal retention by suppressing a PPARδ–CPT1A fatty-acid oxidation program; on its own it made no stones ²⁵.

Skin, melanocytes

UVB raises SLC6A15, a third phenylalanine transporter, and silencing it abolishes the UVB-driven rise in pigment ²⁶.

When it goes wrong

How it is measured

Phenylalanine is measured in plasma or in dried blood spots, newborn screening uses tandem mass spectrometry on the heel-prick card, and every PKU guideline sets its targets in micromoles per liter of blood ^7,37. The two sample types are not interchangeable without a correction ^38,39.

The method this page describes may not survive the decade, and the honest statement of why is worth printing. Newborn screening began with phenylketonuria in the early 1960s and expanded one disease at a time until tandem mass spectrometry let laboratories test for many at once. Newborn genome sequencing identifies many monogenic disorders — but, to date, it cannot identify all the cases that tandem mass spectrometry identifies. It might shorten diagnostic odysseys and improve equity, or worsen disparities and cause harm through overdiagnosis, oversurveillance and overtreatment, and by going beyond established public health screening principles it unsettles the case for screening being mandatory at all ⁴⁰.

Circulating phenylalanine is also sold as a metabolomic marker of mortality risk, and the genetics puts the signal elsewhere. In the UK Biobank, with Cox regression and then two-sample and multivariable Mendelian randomization against parental attained ages, TYROSINE was associated with a shorter lifespan both observationally and genetically — holding up in men after controlling for phenylalanine (−0.91 years, 95% CI −1.60 to −0.21) but not in women. Phenylalanine showed no association with lifespan in either sex once tyrosine was controlled for ⁴¹. The precursor was carrying its product's signal.

• Newborn blood-spot phenylalaninePhenylalanine and tyrosine measured in a dried heel-prick blood spot by tandem mass spectrometry, the method that succeeded Guthrie’s 1963 blood-spot test ^37,42.Measuring tyrosine alongside phenylalanine separated true cases from many false positives flagged by the older fluorometric method ³⁷.A raised level is a starting point: the cause may be a PAH variant, a BH4 disorder or a transient rise, and guidelines now recommend genetic testing at diagnosis ^7,18.
• Monitoring phenylalaninePeople with PKU track their levels with dried blood spots taken at home and posted to the laboratory ³⁸.Capillary spots track venous plasma phenylalanine closely enough for monitoring ³⁸.Spots read lower than plasma, by about 13% in one comparison, so each laboratory needs its own correction factor ^38,39.

Food, supplements and the evidence

What is strange about it

Diet soft drinks carry the warning “contains a source of phenylalanine” because aspartame is a methyl ester of a dipeptide of aspartate and phenylalanine; the warning is for people with PKU ¹¹.

In 1980, a survey of 524 pregnancies in 155 women with PKU found that among mothers whose phenylalanine was 20 mg/dL or higher, 95% had at least one child with intellectual disability, although the children did not have PKU ²⁴.

One treatment for PKU is an enzyme taken from a cyanobacterium, Anabaena variabilis, which splits phenylalanine into trans-cinnamic acid and ammonia instead of making tyrosine. It is coated in polyethylene glycol to shield it from the immune system and injected daily, and immune reactions are still its main problem ^6,10.

Phenylalanine can make a disease worse without causing it, which is a distinction most papers blur and this one does not. Plasma phenylalanine was raised in calcium oxalate stone formers, and genetically predicted phenylalanine was positively associated with kidney stone risk by two-sample Mendelian randomization with no sign of reverse causation. But loading phenylalanine produced no stones by itself: it markedly amplified glyoxylate-induced crystal deposition in mice and oxalate-triggered crystal adhesion to tubular cells, by suppressing a PPARδ–CPT1A fatty-acid oxidation program and raising reactive oxygen species and lipid peroxidation — and activating either PPARδ or CPT1A rescued the signaling and cut the crystal burden ²⁵. A permissive factor is not a cause, and it is still worth measuring.

Where it connects

Sources

47 sources, numbered as they are cited. Every one was checked against PubMed or its publisher before it was cited here; the note under each says what it shows and what it does not.

1. 1
   Joint WHO/FAO/UNU Expert Consultation. Protein and amino acid requirements in human nutrition.World Health Organ Tech Rep Ser · 2007 · (935):1–265PMID 18330140

   Adult requirements, including phenylalanine plus tyrosine at 25 mg/kg/day.

2. 2
   Fitzpatrick PF. Structural insights into the regulation of aromatic amino acid hydroxylation.Curr Opin Struct Biol · 2015 · 35:1–6doi:10.1016/j.sbi.2015.07.004 · PMID 26241318

   PAH, TH and TPH; PAH activated by phenylalanine at its regulatory domain.

3. 3
   Citterio CE, Targovnik HM, Arvan P. The role of thyroglobulin in thyroid hormonogenesis.Nat Rev Endocrinol · 2019 · 15(6):323–338doi:10.1038/s41574-019-0184-8 · PMID 30886364

   Thyroid hormones are built on iodinated tyrosines of thyroglobulin.

4. 4
   Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline.Genet Med · 2014 · 16(2):188–200doi:10.1038/gim.2013.157 · PMID 24385074

   The first inborn error found by population screening; lifelong treatment, 120–360 µmol/L.

5. 5
   Roberts SA, Thorpe JM, Ball RO, Pencharz PB. Tyrosine requirement of healthy men receiving a fixed phenylalanine intake determined by using indicator amino acid oxidation.Am J Clin Nutr · 2001 · 73(2):276–282doi:10.1093/ajcn/73.2.276 · PMID 11157324

   Six men; tyrosine need 6.0 mg/kg/day on top of 9 mg/kg phenylalanine.

6. 6
   Thomas J, Levy H, Amato S, et al. Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM).Mol Genet Metab · 2018 · 124(1):27–38doi:10.1016/j.ymgme.2018.03.006 · PMID 29653686

   261 patients; mean phenylalanine 1,233 to 311 µmol/L at 24 months; frequent adverse events. Manufacturer-funded.

7. 7
   Smith WE, Berry SA, Bloom K, et al. Phenylalanine hydroxylase deficiency diagnosis and management: a 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG).Genet Med · 2025 · 27(1):101289doi:10.1016/j.gim.2024.101289 · PMID 39630157

   Current US guideline: lifelong control at or below 360 µmol/L, including before conception; genetic testing at diagnosis.

8. 8
   Hirasawa T, Satoh Y, Koma D. Production of aromatic amino acids and their derivatives by Escherichia coli and Corynebacterium glutamicum.World J Microbiol Biotechnol · 2025 · 41(2):65doi:10.1007/s11274-025-04264-3 · PMID 39915353

   Industrial fermentation through the shikimate pathway.

9. 9
   Zhu B, Zhang Y, Gao R, et al. Complete biosynthesis of salicylic acid from phenylalanine in plants.Nature · 2025 · 645(8079):218–227doi:10.1038/s41586-025-09175-9 · PMID 40702181

   Four enzymes, named at last, closing a pathway that had been incomplete for decades.

10. 10
    van Spronsen FJ, Blau N, Harding C, et al. Phenylketonuria.Nat Rev Dis Primers · 2021 · 7(1):36doi:10.1038/s41572-021-00267-0 · PMID 34017006

    Review of the disease, its diet and its drugs.

11. 11
    Shaher SAA, Mihailescu DF, Amuzescu B. Aspartame safety as a food sweetener and related health hazards.Nutrients · 2023 · 15(16):3627doi:10.3390/nu15163627 · PMID 37630817

    Aspartame’s structure; the warning for PKU.

12. 12
    Jaffe EK. New protein structures provide an updated understanding of phenylketonuria.Mol Genet Metab · 2017 · 121(4):289–296doi:10.1016/j.ymgme.2017.06.005 · PMID 28645531

    The 452-residue enzyme’s resting and activated forms.

13. 13
    Tai MDS, Kråkenes TA, Gamiz-Arco G, et al. DNAJC12 stabilizes phenylalanine hydroxylase and facilitates its substrate-dependent activation.FASEB J · 2026 · 40(14):e72151doi:10.1096/fj.202504522RR · PMID 42497073

    Four chaperone monomers per enzyme tetramer, and a separate genetic cause of raised phenylalanine.

14. 14
    Blau N. Sepiapterin: from sapropterin to next-generation therapy.Mol Genet Metab · 2026 · 148(3):110110doi:10.1016/j.ymgme.2026.110110 · PMID 42119485

    BH4 as cofactor of the aromatic hydroxylases and nitric oxide synthase; its salvage.

15. 15
    Kulkarni AJ, Rodriguez-Coira J, Stocker N, et al. L-Phenylalanine is a metabolic checkpoint of human Th2 cells.Cell Rep Med · 2025 · 6(12):102466doi:10.1016/j.xcrm.2025.102466 · PMID 41308641

    Human memory CD4 cells, and a job for phenylalanine that is not about tyrosine at all.

16. 16
    Pietz J, Kreis R, Rupp A, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.J Clin Invest · 1999 · 103(8):1169–1178doi:10.1172/JCI5017 · PMID 10207169

    Brain phenylalanine measured by spectroscopy; a large neutral amino acid load blocked its entry.

17. 17
    Scalise M, Galluccio M, Console L, et al. The human SLC7A5 (LAT1): the intriguing histidine/large neutral amino acid transporter and its relevance to human health.Front Chem · 2018 · 6:243doi:10.3389/fchem.2018.00243 · PMID 29988369

    LAT1 with CD98 carries essential amino acids across the placenta and blood–brain barrier.

18. 18
    Opladen T, López-Laso E, Cortès-Saladelafont E, et al. Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies.Orphanet J Rare Dis · 2020 · 15(1):126doi:10.1186/s13023-020-01379-8 · PMID 32456656

    Six disorders; hyperphenylalaninemia in most; dopamine and serotonin deficiency.

19. 19
    Christ SE. Asbjørn Følling and the discovery of phenylketonuria.J Hist Neurosci · 2003 · 12(1):44–54doi:10.1076/jhin.12.1.44.13788 · PMID 12785112

    1934: phenylpyruvic acid in the urine.

20. 20
    Oni OP, Scott B, Schwartz LC, et al. Beyond exercise and appetite: the expanding biology and therapeutic potential of N-lactoyl-phenylalanine.J Pharmacol Exp Ther · 2025 · 393(2):103798doi:10.1016/j.jpet.2025.103798 · PMID 41547294

    A molecule entering human trials while its own receptor, transporters and tissue sources are still undefined — which the review says itself.

21. 21
    Liu H, Li VL, Liu Q, et al. Lac-Phe induces hypophagia by inhibiting AgRP neurons in mice.Nat Metab · 2025 · 7(10):2004–2017doi:10.1038/s42255-025-01377-9 · PMID 40957996

    The mechanism narrowed to one neuron population and one ion channel. Mice.

22. 22
    Han C, Ren C, Zhi T, et al. Disruption of fumarylacetoacetate hydrolase causes spontaneous cell death under short-day conditions in Arabidopsis.Plant Physiol · 2013 · 162(4):1956–1964doi:10.1104/pp.113.216804 · PMID 23743712

    Cited for the end of tyrosine breakdown: fumarylacetoacetate to fumarate and acetoacetate.

23. 23
    Kleta R, Romeo E, Ristic Z, et al. Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder.Nat Genet · 2004 · 36(9):999–1002doi:10.1038/ng1405 · PMID 15286787

    The neutral amino acid transporter of gut and kidney.

24. 24
    Lenke RR, Levy HL. Maternal phenylketonuria and hyperphenylalaninemia: an international survey of the outcome of untreated and treated pregnancies.N Engl J Med · 1980 · 303(21):1202–1208doi:10.1056/NEJM198011203032104 · PMID 7421947

    524 pregnancies in 155 women.

25. 25
    Li P, Ma Y, Li Y, et al. Phenylalanine primes renal tubular redox vulnerability and calcium oxalate crystal retention through a PPARδ-CPT1A fatty-acid oxidation axis.Redox Biol · 2026 · 95:104292doi:10.1016/j.redox.2026.104292 · PMID 42431158

    Careful about causation in a way worth copying: the amino acid made no stones on its own.

26. 26
    Zhou S, Ouyang Y, Hu Y, et al. UVB enhances SLC6A15-mediated phenylalanine transport to promote melanogenesis.J Photochem Photobiol B · 2025 · 274:113329doi:10.1016/j.jphotobiol.2025.113329 · PMID 41352278

    A third transporter, switched on by sunlight, and a Mendelian randomization estimate for a pigmentation disorder.

27. 27
    Hillert A, Anikster Y, Belanger-Quintana A, et al. The genetic landscape and epidemiology of phenylketonuria.Am J Hum Genet · 2020 · 107(2):234–250doi:10.1016/j.ajhg.2020.06.006 · PMID 32668217

    Global prevalence and variant spectrum.

28. 28
    Romani C, Huijbregts S, van Spronsen FJ, et al. Meta-analysis of cognitive outcomes in children and adults with early treated phenylketonuria: results across functions.Mol Genet Metab · 2025 · 146(1–2):109210doi:10.1016/j.ymgme.2025.109210 · PMID 40753692

    About 0.5 SD below controls across functions, in children and adults.

29. 29
    Dóczi TI, Vaghela S, Obeng GD, et al. Epidemiology of hyperphenylalaninemia: a systematic review and meta-analysis.Sage Open Pediatr · 2026 · 13:30502225251414610doi:10.1177/30502225251414610 · PMID 41625943

    4,297 records down to 97 in the model, with confidence intervals and the two diagnoses separated. Authors from Moderna and a contract research institute.

30. 30
    Boehnke A, Müller LM, Heidecke C, et al. Care of patients with phenylketonuria (PKU) in Germany — a claims data analysis from 2013 to 2023.Orphanet J Rare Dis · 2026 · 21(1):04467doi:10.1186/s13023-026-04467-3 · PMID 42393732

    Ten years of whole-population billing records rather than a clinic cohort. Conducted by and with authors from PTC Therapeutics.

31. 31
    Muntau AC, Longo N, Ezgu F, et al. Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial.Lancet · 2024 · 404(10460):1333–1345doi:10.1016/S0140-6736(24)01556-3 · PMID 39368841

    157 enrolled, 114 responsive; −63% against +1%. Manufacturer-funded.

32. 32
    Lah M, Kopesky J, Vucko E. Sepiapterin: a distinct, dual mechanism of action that leads to potential treatment benefits across the spectrum of phenylketonuria disease severities.Adv Ther · 2026doi:10.1007/s12325-026-03607-2 · PMID 42250073

    Approval in 2025 in several countries including the US.

33. 33
    Giżewska M, Inwood A, Tyčová R, et al. Efficacy and safety of sepiapterin versus sapropterin in patients with phenylketonuria: results from the phase 3, randomized, crossover, open-label, active-controlled AMPLIPHY trial.Metabolism · 2026 · 178:156513doi:10.1016/j.metabol.2026.156513 · PMID 41616812

    The two cofactor drugs put against each other, with sapropterin at its maximum licensed dose.

34. 34
    van Spronsen F, Peters H, Margvelashvili L, et al. Effect of long-term sepiapterin treatment on dietary phenylalanine tolerance in patients with phenylketonuria: interim results from the phase 3 APHENITY extension study.Genet Med · 2026 · 28(4):101683doi:10.1016/j.gim.2026.101683 · PMID 41537382

    169 patients, a median of 73 weeks, and the outcome patients actually ask about: how much food.

35. 35
    Harding CO, Whitehall KB, Lilienstein J, et al. Long-term management strategies for pegvaliase use in phenylketonuria: lessons learned from the phase-3 PRISM open-label extension study.Genet Med · 2025 · 27(8):101459doi:10.1016/j.gim.2025.101459 · PMID 40411344

    A model built on participant-level data, against the intuitive move. Several authors work for the manufacturer.

36. 36
    Conde-Giménez M, Salillas S, Galiana-Cameo M, et al. Variant-dependent pharmacological rescue of phenylalanine hydroxylase supports a precision therapeutic strategy for phenylketonuria.Biomed Pharmacother · 2026 · 199:119371doi:10.1016/j.biopha.2026.119371 · PMID 41990466

    26 compounds against 8 variants in cells, with a crystal structure. Cells, not patients.

37. 37
    Chace DH, Millington DS, Terada N, et al. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry.Clin Chem · 1993 · 39(1):66–71PMID 8419060

    The tandem mass spectrometry method; tyrosine separated false positives.

38. 38
    van Vliet K, van Ginkel WG, van Dam E, et al. Dried blood spot versus venous blood sampling for phenylalanine and tyrosine.Orphanet J Rare Dis · 2020 · 15(1):82doi:10.1186/s13023-020-1343-7 · PMID 32245393

    45 patients; spots track plasma phenylalanine; laboratory-specific correction needed.

39. 39
    Carling RS, Barclay Z, Cantley N, et al. Investigation of the relationship between phenylalanine in venous plasma and capillary blood using volumetric blood collection devices.JIMD Rep · 2023 · 64(6):468–476doi:10.1002/jmd2.12398 · PMID 37927487

    51 patients; capillary blood read on average 13% below plasma.

40. 40
    Ross LF, Ormond KE. Newborn sequencing: the promise and perils.Annu Rev Genomics Hum Genet · 2025 · 26(1):401–423doi:10.1146/annurev-genom-121123-115349 · PMID 41889322

    The screening program that began with this disease, and the question of what replaces it.

41. 41
    Zhao JV, Sun Y, Zhang J, Ye K. The role of phenylalanine and tyrosine in longevity: a cohort and Mendelian randomization study.Aging (Albany NY) · 2025 · 17(10):2500–2533doi:10.18632/aging.206326 · PMID 41045493

    UK Biobank, with multivariable Mendelian randomization to separate the two. The separation is the result.

42. 42
    Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants.Pediatrics · 1963 · 32:338–343PMID 14063511

    The original blood-spot screening test.

43. 43
    van Wegberg AMJ, MacDonald A, Ahring K, et al. European guidelines on diagnosis and treatment of phenylketonuria: first revision.Mol Genet Metab · 2025 · 145(2):109125doi:10.1016/j.ymgme.2025.109125 · PMID 40378670

    87 statements, 21 professionals, 14 meetings, and a literature search that stops in September 2022.

44. 44
    Daly A, Pinto A, Evans S, et al. Protein substitute absorption: a randomised controlled trial comparing CGMP vs. amino acids vs. micellar casein in healthy volunteers.Nutrients · 2025 · 17(16):2671doi:10.3390/nu17162671 · PMID 40871699

    20 healthy volunteers, three products, blood sampled over four hours. The claim being tested is 'more like real protein'.

45. 45
    Walsh NE, Ramamurthy S, Schoenfeld L, Hoffman J. Analgesic effectiveness of D-phenylalanine in chronic pain patients.Arch Phys Med Rehabil · 1986 · 67(7):436–439PMID 3524509

    30 patients, crossover: no difference from placebo.

46. 46
    Beckmann H, Athen D, Olteanu M, Zimmer R. DL-phenylalanine versus imipramine: a double-blind controlled study.Arch Psychiatr Nervenkr · 1979 · 227(1):49–58doi:10.1007/BF00585677 · PMID 387000

    27 completers; no placebo arm.

47. 47
    Liao Z, Parumasivam T, Xiao Z, et al. Emerging therapeutic and cosmeceutical applications of phenylalanine and its metabolites.Cutan Ocul Toxicol · 2026 · 45(1):127–144doi:10.1080/15569527.2026.2612999 · PMID 41532887

    A review enthusiastic about the applications and explicit that the long-term human safety data do not exist.